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Prior to 1990, six major antiepileptic drugs (AEDs) were available for treating all forms of epilepsy.  These agents include carbamazepine, ethosuximide, 
phenobarbital, phenytoin, primidone, and valproic acid.  These conventional agents have been used as monotherapy and in combined regimens in newly diagnosed 
and refractory cases, yet 20% to 30% of epileptic patients are refractory to these drugs.  Also, complex pharmacokinetic parameters, need for monitoring, drug 
interactions, teratogenic potential, troublesome side effects, and adverse impact on patient quality-of-life provide challenges for patients and clinicians alike.14 
Since 1990 the FDA has approved several new AEDs.  These include gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, zonisamide, 
and felbamate.  These newer agents have fewer safety and tolerability problems and are easier to use.  Even though they are more expensive than the older AED’s, 
their expense may be offset by their potential benefits.14-17  Among the newer agents, only oxcarbazepine is approved for use as monotherapy for the treatment of 
newly diagnosed patients.  Lamotrigine and oxcarbazepine are also approved as monotherapy for refractory partial epilepsy.  All of the eight newer AEDs 
(gabapentin, lamotrigine, felbamate, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide) are approved for refractory partial epilepsy as add-on 
therapy. 
Recently, the American Academy of Neurology (AAN) and the American Epilepsy Society (AES) presented guidelines for use of these newer agents.  Tiagabine, 
levetiracetam, and zonisamide are not yet recommended for monotherapy by the FDA or in these guidelines.15,16
Comparison of FDA-Approved Antiepileptic Drugs 
Drug FDA Labeled Indications Dosage Range18,19 Daily Cost* Serious Adverse Effects15,16,19 Significant Drug Interactions19,20 Comments20 
Carbamazepine 
(Tegretol) 
• Partial seizures with 
complex 
symptomatology 
• Generalized tonic-
clonic seizures (grand 
mal), mixed seizure 
patterns 1  
• Adults: 800 mg initially to 
1,200 mg daily maximum, 
increasing at weekly intervals 
by 200 mg 
• Children: varies by age per 
weight 
• $1.40 per day 
Syncope, blood dyscrasias,  
visual difficulties, hepatitis, 
rash, Stevens-Johnson 
syndrome, pancreatitis 
Calcium channel blockers, 
clarithromycin, clozapine, 
contraceptives, cyclosporin, 
CYP3A4 inhibitors, danazol, 
diclofenac, doxycycline,  
erythromycin, haloperidol, imatinib, 
isoniazid, lamotrigine, 
mebendazole, methadone, 
nefazodone, phenytoin, propofol, 
propoxyphene, protease inhibitors, 
quinidine, SSRIs, warfarin 
• For newly 
diagnosed, new-
onset, and refractory 
epilepsy14-16 
• Therapeutic range: 4 
to 12 mcg/mL 
• Liver function tests 
should be performed 
at baseline and 
periodically 
Ethosuximide 
(Zarontin)        
• Generalized absence, 
Control of absence 
(petit mal) epilepsy2 
• Adults: 500 mg initially to 
1,500 mg daily maximum, 
increase by 250 mg every 4 to 
7 days as tolerated 
• Children: 3 to 6 years, 15 mg 
(maximal initial dose: 250 mg) 
to 40 mg/kg/day maximum, 
titrate every 4 to 7 days as 
tolerated 
• $6.55 per day 
Blood dyscrasias, lupus, 
Stevens-Johnson syndrome, 
aggression  
Azole antifungals, clarithromycin, 
diclofenac, isoniazid, nefazodone, 
nicardipine, propofol, protease 
inhibitors, quinidine, telithromycin  
• For newly 
diagnosed, new-
onset, and refractory 
epilepsy14-16 
• Usual therapeutic 
range: 40 to 100 
mcg/mL 
• Liver function tests 
should be performed 
at baseline and 
periodically 
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Drug FDA Labeled Indications Dosage Range18,19 Daily Cost* Serious Adverse Effects15,16,19 Significant Drug Interactions19,20 Comments 
Phenobarbital • Generalized onset 
myoclonic  
• Partial onset, 
generalized onset 
tonic-clonic19 
• Adults: 120 mg to 180 mg 
daily (oral) 
• Children: varies by age per 
weight 
• $0.24 per day 
Rash, Stevens-Johnson 
syndrome, blood dyscrasias, 
angioedema 
Azole antifungals, calcium channel 
blockers, chloramphenicol, 
clomipramine, contraceptives, 
cyclosporin, disopyramide, 
doxycycline, gemfibrozil, isoniazid, 
lamotrigine, methadone, 
methoxyflurane, modafinil, non-
nucleoside reverse transcriptase 
inhibitors, omeprazole, quinidine, 
telithromycin, ticlopidine, tricyclic 
antidepressants, warfarin  
 
• For newly 
diagnosed, new-
onset, and refractory 
epilepsy14-16 
• Therapeutic range: 
15 to 40 mcg/mL 
Phenytoin 
(Dilantin) 
• Partial onset 
(psychomotor) seizure  
• Generalized onset 
tonic-clonic3 
• Adults: Loading dose needed 
for initiation, then 4 mg 
initially to 6 mg/kg/day 
maximum 
• Children: varies by age per 
weight 
• $0.80 per day 
Hepatotoxicity, blood 
dyscrasias, rash, Steven’s 
Johnson syndrome, 
osteomalacia, lupus, lymphoma 
Azole antifungals, calcium channel 
blockers, carbamazepine, 
chloramphenicol, cimetidine, 
contraceptives, cyclosporine, 
disopyramide, disulfiram, 
doxycycline, felbamate, 
flurbiprofen, gemfibrozil, HMG-
CoA reductase inhibitors (select), 
ibuprofen, indomethacin,  isoniazid, 
lamotrigine, mefenamic acid, 
modafinil,  nucleoside reverse 
transcriptase inhibitors, 
pioglitazone, piroxicam, quinidine, 
rifabutin, rifampin, sirolimus, 
SSRIs, ticlopidine, warfarin 
 telithromycin, warfarin, non- 
phenobarbital 
 
• For newly 
diagnosed, new-
onset, and refractory 
epilepsy14-16 
• Therapeutic range: 
10 to 20 mcg/mL 
(free levels: 1 to 2 
mcg/mL) 
Primidone  
(Mysoline) 
• Partial onset  
• Generalized onset 
tonic-clonic, grand 
mal, psychomotor, 
focal seizures4 
• Adults: 100 mg initially to 
2,000 mg maximum daily, 
increase by 100 to 125 mg 
increments every 3 days as 
tolerated 
• Children: varies by age per 
weight 
• $3.90 per day 
 
 
 
 
Thrombocytopenia, anemia, 
dyspnea, lupus-like syndrome 
Lamotrigine, quinidine • For newly 
diagnosed, new-
onset, and refractory 
epilepsy14-16 
• Adjust dose in renal 
impairment 
• Therapeutic range: 5 
to 12 mcg/mL 
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Drug FDA Labeled Indications Dosage Range18,19 Daily Cost* Serious Adverse Effects15,16,19 Significant Drug Interactions19,20 Comments 
Valproic Acid 
(Depakene) 
• Generalized absence  
• Generalized onset 
myoclonic  
• Partial onset  
• Generalized onset 
tonic-clonic, complex 
partial seizures, 
absence seizures 
(simple and complex)5 
• Adults: 10 mg initially to 60 
mg/kg/day maximum, increase 
by 5 to 10 mg/kg/day weekly 
as tolerated 
• Children: not recommended 
due to hepatotoxicity 
• $7.52 per day 
Hepatotoxicity, pancreatitis, 
blood dyscrasias, rash, Stevens-
Johnson syndrome, 
hyperammonemia, anaphylaxis, 
psychosis 
Felbamate, lamotrigine, macrolide 
antibiotics 
• For newly 
diagnosed, new-
onset, and refractory 
epilepsy14-16 
• Therapeutic range: 
50 to 100 mcg/mL 
• Liver function tests 
should be performed 
at baseline and at 
frequent intervals 
especially during the 
first 6 months 
Felbamate  
(Felbatol) 
• Monotherapy or 
adjunctive treatment 
for partial seizures in 
adults 
• Adjunctive treatment 
in generalized or 
partial seizures 
associated with 
Lennox-Gastaut 
syndrome in children. 
Note: not for first line 
treatment**6  
• Adults: 1,200 mg initially to 
3,600 mg maximum daily 
• Children: 15 initially to 45 
mg/kg/day maximum 
Titrate with increases at two week 
intervals 
• $11.99 per day 
Aplastic anemia, liver failure Azole antifungals, calcium channel 
blockers, contraceptives, diclofenac, 
isoniazid, macrolide antibiotics, 
nefazodone, phenytoin,  propofol, 
protease inhibitors, quinidine, 
valproic acid 
• For refractory 
epilepsy14-16 
• Monitor liver 
function enzymes 
and bilirubin at 
baseline and every 1 
to 2 weeks 
Gabapentin 
(Neurontin) 
• Adjunctive therapy in 
the treatment of partial 
seizures with and 
without secondary 
generalization in 
patients over 12 years 
of age 
• Adjunctive therapy in 
the treatment of partial 
seizures in pediatric 
patients age 3 to 12 
years7 
• Adults: 300 mg initially to 
3,600 mg maximum daily  
• Children: 10 mg initially to 
50 mg/kg/day maximum 
Titrate and increase slowly as 
tolerated 
• $15.60 per day 
Aggression None • For newly 
diagnosed, new-
onset, and refractory 
epilepsy14-16 
• FDA unapproved 
indication: newly 
diagnosed 
partial/mixed 
seizures as 
monotherapy (Level 
A)*** 
• Slow titration 
minimizes adverse 
effects 
• Serum level 
monitoring not 
needed 
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Drug FDA Labeled Indications Dosage Range18,19 Daily Cost* Serious Adverse Effects15,16,19 Significant Drug Interactions19,20 Comments 
Lamotrigine 
(Lamictal) 
• Adjunctive therapy for 
partial seizures in 
adults and pediatric 
patients (>2 years of 
age)  
• Adjunctive therapy for 
the generalized 
seizures of Lennox-
Gastaut syndrome in 
adult and pediatric 
patients (>2 years of 
age) 
• Conversion to 
monotherapy in adults 
with partial seizures 
receiving treatment 
with carbamazepine, 
phenytoin, 
phenobarbital, 
primidone, or 
valproate as single 
AED8 
• Adults: as monotherapy,  
50 mg initially to 500 mg 
maximum daily   
• Children: as monotherapy 0.3 
mg initially  to 8 mg/kg/day 
maximum 
Titrate and increase dose 
gradually every two weeks as 
tolerated 
• $15.83 per day 
Rash (including Stevens 
Johnson and toxic epidermal 
necrolysis), hypersensitivity 
reactions including hepatic and 
renal failure, disseminated 
intravascular coagulation, 
arthritis 
Barbiturates, carbamazepine, 
contraceptives, phenytoin, 
primidone, quinidine, valproic acid 
• For newly 
diagnosed, new-
onset, and refractory 
epilepsy14-16 
• FDA unapproved 
indication: newly 
diagnosed 
partial/mixed 
seizures as 
monotherapy (Level 
A)***, newly 
diagnosed absence 
seizures in children 
as add-on (Level 
B)*** 
• Serum level 
monitoring not 
needed 
Levetiracetam 
(Keppra) 
• Adjunctive therapy in 
the treatment of partial 
onset seizures in 
adults9 
• Adults: 500 mg initially  to 
3,000 mg maximum daily 
• Children: no recommended 
doses however, clinical trials 
have used 10 mg initially to 60 
mg/kg/day maximum 
Titrate and increase at two week 
intervals as tolerated 
• $12.40 per day 
Psychosis, blood dyscrasias, 
suicide attempts 
None • For refractory 
epilepsy14-16 
• Serum level 
monitoring not 
needed 
Oxcarbazepine 
(Trileptal) 
• Monotherapy or 
adjunctive therapy  in 
partial seizures in 
adults and children 
aged 4 to 1610 
• Adults: 300 mg initially to 
2,400 mg maximum daily, 
increase at 3 to 7 day intervals 
as tolerated 
• Children: 8 mg/kg/day 
(maximum initial dose 600 mg 
daily) increasing by 8 to 10 
mg/kg/day as tolerated at 3 to 
7 day intervals 
• $14.66 per day 
Hyponatremia, rash Contraceptives • For newly 
diagnosed, new-
onset, and refractory 
epilepsy14-16 
• Monitor serum 
sodium during first 
3 month and more 
frequently with 
hyponatremic drugs 
• Level monitoring 
not needed 
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Drug FDA Labeled Indications Dosage Range18,19 Daily Cost* Serious Adverse Effects15,16,19 Significant Drug Interactions19,20 Comments 
Tiagabine  
(Gabitril) 
• Adjunctive therapy in 
adults and children 12 
years and older in the 
treatment of partial 
seizures11 
 
• Adults: 4 mg to 56 mg daily, 
starting at 4 mg and increasing 
by 4 to 8 mg at weekly 
intervals 
• Children: 12 years and >: 
0.25 mg/kg/day initially with 
increments of 0.25 to 5 
mg/kg/day maximum at two to 
four week intervals up to 1 to 
2 mg/kg/day 
• $8.60 per day 
Nonconvulsive status 
epilepticus, stupor 
Azole antifungals, calcium channel 
blockers, diclofenac, isoniazid, 
macrolide antibiotics, nefazodone, 
propofol, protease inhibitors, 
quinidine 
• For refractory 
epilepsy14-16 
• Monitor complete 
blood counts, renal 
function tests, liver 
function tests, and 
routine blood 
chemistry 
periodically 
• Serum level 
monitoring not 
needed 
Topiramate 
(Topamax) 
• Adjunctive therapy for 
adults and pediatric 
patients ages 2-16 
years with partial onset 
seizures, or primary 
generalized tonic-
clonic seizures, and in 
patients 2 years of age 
and older with seizures 
associated with 
Lennox-Gastaut 
syndrome12 
• Adults: 25 mg initially to not 
more than 1,600 mg daily with 
dose increases of 25 mg 
weekly as tolerated 
• Children: 1 mg initially to 9 
mg/kg/day maximum with 1 to 
3 mg/kg/day increases made 
weekly as tolerated 
• $39.18 per day 
Nephrolithiasis, open angle 
glaucoma, hypohidrosis, 
depression, psychosis, metabolic 
acidosis 
Contraceptives • For newly 
diagnosed, new-
onset, and refractory 
epilepsy14-16 
• FDA unapproved 
indication: newly 
diagnosed 
partial/mixed 
seizures as 
monotherapy (Level 
A)***, refractory 
partial epilepsy as 
monotherapy (Level 
A)*** 
• Adjust dose in renal 
impairment 
• Slow titration 
minimizes adverse 
effects 
• Monitor serum 
bicarbonate at 
baseline and 
periodically 
• Serum level 
monitoring not 
needed 
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Drug FDA Labeled Indications Dosage Range18,19 Daily Cost* Serious Adverse Effects15,16,19 Significant Drug Interactions19,20 Comments 
Zonisamide 
(Zonegran) 
• Adjunctive therapy in 
the treatment of partial 
seizures in adults13 
 
• Adults: 100 mg initially to 
600 mg daily maximum, 
titrate in 100 mg increments at 
two week intervals  
• Children: 2 mg initially to 8 
(possibly 12) mg/kg/day 
maximum titrated at two week 
intervals as tolerated 
• $12.60 per day 
Rash, renal calculi, hypohidrosis Azole antifungals, calcium channel 
blockers, diclofenac, isoniazid, 
macrolide antibiotics, nefazodone, 
propofol, protease inhibitors, 
quinidine 
• For refractory 
epilepsy14-16 
• Levels of 20 to 30 
mcg/mL associated 
with efficacy 
• Serum level 
monitoring not 
needed 
• Monitor renal 
function  
* Daily cost is based on maximum adult dosage (70 kg). Cost information is approximate as of the time this chart was prepared. It is based on manufacturer stated internet website 
prices, observed retail pharmacy prices, and www.drugstore.com listings. Actual selling prices may differ. 
** Use only if patients unresponsive to standard drug and where risk/benefit ratio supports use.6 
*** American Academy of Neurology (AAN) and the American Epilepsy Society (AES) Level A or B Use Recommendations.  These evidence-based guidelines provide 
recommendations for use based on at least one prospective, randomized controlled clinical trial (RCT) with defined requirements (Level A) or at least one prospective matched group 
cohort study, lesser RCT, or at least three controlled trials (Level B).15,16 
 
Users of this document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our editors have researched the information with input from experts, government agencies, and national 
organizations.  Information and Internet links in this article were current as of the date of publication. 
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